Oncology Grand Rounds Series: Part 5 — Breast Cancer

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope S Rugo and Ms Gretchen Santos.

2.1 contact hours

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CNE credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CNE evaluation
CNE information and faculty disclosures
Select publications
PowerPoint slides

Introduction
Program overview: Dr Love
HER2-Positive Localized and Metastatic Breast Cancer (BC)
Case (Ms O’Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1
Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1
Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study
Case (Ms O’Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain
ER-Positive, HER2-Negative Metastatic Disease
Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole
Case (Ms O’Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy
Triple-Negative Metastatic BC
Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab